State-Level Ketamine Therapy Regulations: 2025 Landscape

A Regulatory Landscape in Flux

State-level ketamine therapy regulations have become one of the most rapidly evolving areas of healthcare policy in the United States. As the use of ketamine for psychiatric and pain conditions has expanded — particularly through telehealth platforms and at-home prescribing models — state legislatures, medical boards, and pharmacy boards have responded with a patchwork of regulations that vary significantly from state to state.

The result is a complex and sometimes contradictory regulatory environment that affects patients, providers, and pharmacies across the country. This article provides an overview of the key regulatory trends and developments shaping ketamine therapy access in 2025.

Key Regulatory Areas

Telehealth Prescribing of Controlled Substances

One of the most consequential regulatory issues is the prescribing of ketamine and other controlled substances via telehealth. During the COVID-19 public health emergency, the DEA temporarily waived the requirement for an in-person evaluation before prescribing controlled substances, allowing telehealth-only prescribing to flourish. As these temporary flexibilities have been reevaluated, the regulatory landscape has become more restrictive in some jurisdictions.

Federal developments:

• The DEA has proposed rules that would reinstate in-person evaluation requirements for controlled substance prescriptions initiated via telehealth, with specific exemptions for certain substances and clinical scenarios
• The proposed rules have generated significant debate, with advocates arguing that telehealth access is essential for patients in underserved areas and opponents citing safety concerns about unsupervised controlled substance use

State-level responses have varied:

• Some states have enacted their own telehealth prescribing rules that are more permissive than the proposed federal standards
• Others have implemented stricter requirements, including mandatory in-person evaluations before initial ketamine prescriptions
• Several states have specifically addressed ketamine in their telehealth legislation, distinguishing it from other controlled substances

Supervision and Monitoring Requirements

States are increasingly establishing specific requirements for clinical supervision during ketamine administration:

• In-clinic requirements: Some states have enacted or proposed rules requiring physician supervision (not just nurse practitioner or physician assistant oversight) for IV ketamine administration
• At-home monitoring: Several states require specific monitoring protocols for patients receiving at-home ketamine, including treatment sitter requirements, home blood pressure monitoring, and minimum follow-up frequencies
• Spravato-specific rules: While the federal REMS program establishes baseline requirements for Spravato administration, some states have layered additional requirements on top of the federal framework

Compounding Pharmacy Regulations

The role of compounding pharmacies in ketamine therapy has attracted regulatory attention:

• State pharmacy boards have issued guidance on compounding standards specific to ketamine preparations
• Some states have increased inspection and quality-testing requirements for pharmacies compounding ketamine
• The distinction between 503A pharmacies (which compound for individual prescriptions) and 503B outsourcing facilities (which can compound larger quantities without individual prescriptions) has been a focus of regulatory clarification

Practitioner Qualifications

Several states have considered or implemented requirements regarding the qualifications of practitioners who prescribe or administer ketamine for psychiatric purposes:

• Proposals have ranged from requiring specific training in ketamine therapy to requiring board certification in psychiatry or anesthesiology
• Professional organizations have developed voluntary credentialing programs, and some states have referenced these in their regulatory frameworks
• The scope of practice for nurse practitioners and physician assistants in ketamine prescribing has been addressed differently across states

Notable State Actions

States With More Restrictive Approaches

Several states have taken steps to increase oversight of ketamine therapy:

• New York: Has implemented requirements for enhanced documentation and reporting for off-label ketamine prescribing, including mandatory reporting to the state's Prescription Drug Monitoring Program (PDMP)
• California: The medical board has issued guidance on standards of care for ketamine therapy, including supervision requirements and patient selection criteria
• Florida: Has enacted legislation specifically addressing ketamine clinic operations, including facility licensing requirements and clinical staffing standards

States With More Permissive Approaches

Other states have adopted frameworks that facilitate broader access:

• Colorado: Has established a relatively permissive framework for psychedelic and ketamine-assisted therapies, building on its broader psychedelic reform legislation
• Oregon: Has developed regulatory frameworks that accommodate ketamine therapy within its broader supervised psilocybin and psychedelic therapy programs
• Texas: Has maintained relatively open prescribing practices for ketamine, with fewer state-specific restrictions than some other large states

States Under Active Legislative Consideration

As of 2025, multiple state legislatures have pending bills related to ketamine therapy regulation. Common themes in proposed legislation include:

• Establishing minimum clinical standards for ketamine therapy providers
• Defining scope-of-practice boundaries for different provider types
• Addressing insurance coverage mandates for ketamine therapy
• Regulating the marketing and advertising of ketamine services
• Establishing patient registries or reporting requirements

Impact on Patients and Providers

Geographic Disparities

The state-by-state nature of ketamine regulation creates geographic disparities in access. Patients in states with permissive regulations may have broad access to multiple treatment modalities, while those in more restrictive states may face fewer options. These disparities are particularly consequential for patients in rural areas, who may already face limited provider availability.

Provider Compliance Challenges

Providers operating across state lines — particularly telehealth-based services — face the challenge of complying with different regulatory requirements in each state where they practice. This complexity has led some national telehealth ketamine companies to limit their service areas to states with more favorable regulatory environments.

Patient Safety Implications

The patchwork of regulations raises patient safety considerations. States with minimal oversight may have higher rates of inadequate screening, insufficient monitoring, and inappropriate prescribing. Conversely, overly restrictive regulations may limit access for patients who would benefit from treatment, potentially driving them toward unregulated or underground alternatives.

Federal-State Interactions

The interplay between federal and state regulations adds another layer of complexity:

• DEA scheduling and enforcement: Ketamine's Schedule III status is a federal classification, but states can impose additional restrictions beyond federal requirements
• FDA REMS program: The Spravato REMS operates at the federal level, but states can add supplementary requirements
• Interstate telehealth: The regulation of telehealth prescribing across state lines involves both federal and state jurisdictions, with ongoing debates about which level of government should have primary authority

Looking Ahead

The regulatory landscape for ketamine therapy is expected to continue evolving through 2025 and beyond. Key factors that will shape this evolution include:

• Federal rulemaking on telehealth prescribing of controlled substances
• Outcomes of pending state legislation
• Growth of the clinical evidence base, which influences both legislative and medical board decision-making
• Industry consolidation and lobbying efforts by ketamine provider organizations
• Patient advocacy and public awareness
• Potential new FDA approvals for ketamine-related products

Patients and providers are encouraged to stay informed about the regulations in their specific state and to consult legal and regulatory resources relevant to their jurisdiction.

Note: This article is for educational purposes only and does not constitute legal or medical advice. Regulatory information is subject to change, and readers should consult current state and federal regulations. For general information about ketamine therapy and how to find a provider, see our partner resources and legal counsel for specific guidance.

References

• FDA: Drug Information — FDA resource on federal drug regulation, REMS programs, and controlled substance oversight
• StatPearls: Ketamine — Clinical reference covering ketamine's Schedule III classification and prescribing regulations
• MedlinePlus: Esketamine Nasal Spray — Drug information on Spravato including REMS requirements that interact with state regulations
• NIMH: Depression — National Institute of Mental Health information on depression treatment access and policy